OPKO and Pfizer Announce Positive Phase 3 Top-Line Results for Somatrogon, an Investigational Long-Acting Human Growth Hormone to Treat Children wi false

אופקו הלת', אינק	2 380
OPKO HEALTH, INC
Corporation no: 2279206	10017

	Israel Securities Authority			Tel Aviv Stock Exchange		C002 ( Public )		Reported via MAGNA:	22/10/2019
	www.isa.gov.il			www.tase.co.il				Reference:	2019-02-089301	Time of broadcast: 09:03 09:01:26

Immediate Report

Regulation 4 of the Securities Regulations, (Periodic and Immediate Reports of Foreign Corporation) 5761-2000

The corporation is a foreign private issuer as defined by U.S. Securities Laws.

Attached hereto is a report on

OPKO and Pfizer Announce Positive Phase 3 Top-Line Results for Somatrogon, an Investigational Long-Acting Human Growth Hormone to Treat Children with Growth Hormone Deficiency אופקו ופייזר מכריזות על תוצאות חיוביות בניסוי שלב 3 בטיפול בילדים הסובלים מ GHD

דיווח.pdf

References of previous documents relating to this matter(the reference does not constitute incorporation by reference):
Stock Exchange/Market: NASDAQ GSM	Date of revision of form structure: 06/08/2019
Address: Ashlegan 16 , Kiryat Gat 8211804   Israel , Tel: 08-9300051 , Fax: 08-9300091
E-mail address: yphilip@opko.com   Company site: Www.Opko.Com
Previous names of reporting entity:
Name of the Signatory: Gerzi Ilan Position of Signatory in the reporting corporation: Legal Adviser Name of Employer Company: PEARL COHEN ZEDEK LATZER BARATZ
Address: Azrieli, Round Tower 18f 1 , Tel Aviv 67021 Telephone: 03-6073777 Facsimile: 03-6073778 E-mail: IGERZI@PEARLCOHEN.COM 1